Literature DB >> 19173296

Regulation of deoxycholate induction of CXCL8 by the adenomatous polyposis coli gene in colorectal cancer.

Nathaniel S Rial1, Gwendal Lazennec, Anil R Prasad, Robert S Krouse, Peter Lance, Eugene W Gerner.   

Abstract

Elevated deoxycholic acid (DCA), mutations in the adenomatous polyposis coli (APC) gene and chronic inflammation are associated with increased risk of colorectal cancer. APC status was manipulated to determine whether DCA mediates inflammatory molecules in normal or initiated colonic mucosa. DCA increased steady state mRNA and protein levels of CXCL8 in cells which do not express wild-type APC. Steady-state CXCL8 mRNA and protein were suppressed when cells with conditional expression of wild-type APC were exposed to DCA. Immunostaining did not detect CXCL8 in normal human colonic mucosa. CXCL8 was expressed in adenomatous polyps and adenocarcinomas. CXCL8 expression correlated with nuclear beta-catenin localization in epithelial cells of adenomas, but was associated with endothelial cells and neutrophils in the adenocarcinomas. DCA-mediated CXCL8 promoter-reporter activity was elevated in a mutant APC background. Wild-type APC suppressed this effect. Mutation of activator protein-1 (AP-1) or nuclear factor kappa B (NF-kappaB) sites suppressed the activation of the CXCL8 promoter-reporter by DCA. Chromatin immunoprecipitation revealed that AP-1 and NF-kappaB binding to the 5'-promoter of CXCL8 was induced by DCA. The beta-catenin transcription factor was bound to the 5'-promoter of CXCL8 in the absence or presence of DCA. Phenotypic assays determined that DCA-mediated invasion was blocked by antibody-directed against CXCL8 or wild-type APC. CXCL8 exposure led to matrix metalloproteinase-2 production and increased invasion on laminin-coated filters. These data suggest that DCA-mediated CXCL8 occurs in initiated colonic epithelium and neutralizing CXCL8 could reduce the invasive potential of tumors. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19173296      PMCID: PMC2669776          DOI: 10.1002/ijc.24226

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  62 in total

1.  Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis.

Authors:  M Luca; S Huang; J E Gershenwald; R K Singh; R Reich; M Bar-Eli
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

Review 2.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

Review 3.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

4.  Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro.

Authors:  R Brew; J S Erikson; D C West; A R Kinsella; J Slavin; S E Christmas
Journal:  Cytokine       Date:  2000-01       Impact factor: 3.861

5.  The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression.

Authors:  I M Shih; J Yu; T C He; B Vogelstein; K W Kinzler
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

6.  Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice.

Authors:  D A Arenberg; S L Kunkel; P J Polverini; M Glass; M D Burdick; R M Strieter
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

7.  Apoptosis and APC in colorectal tumorigenesis.

Authors:  P J Morin; B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

8.  Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8.

Authors:  N Mukaida; M Shiroo; K Matsushima
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

9.  92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer.

Authors:  B S Nielsen; S Timshel; L Kjeldsen; M Sehested; C Pyke; N Borregaard; K Danø
Journal:  Int J Cancer       Date:  1996-01-03       Impact factor: 7.396

10.  Molecular mechanism of interleukin-8 gene expression.

Authors:  N Mukaida; S Okamoto; Y Ishikawa; K Matsushima
Journal:  J Leukoc Biol       Date:  1994-11       Impact factor: 4.962

View more
  7 in total

1.  Loss of organic anion transporting polypeptide 1a1 increases deoxycholic acid absorption in mice by increasing intestinal permeability.

Authors:  Youcai Zhang; Iván L Csanaky; Lois D Lehman-McKeeman; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2011-09-13       Impact factor: 4.849

Review 2.  Secondary Bile Acids and Tumorigenesis in Colorectal Cancer.

Authors:  Yujing Liu; Shengan Zhang; Wenjun Zhou; Dan Hu; Hanchen Xu; Guang Ji
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

3.  Extracellular DNA in pancreatic cancer promotes cell invasion and metastasis.

Authors:  Fushi Wen; Alex Shen; Andrew Choi; Eugene W Gerner; Jiaqi Shi
Journal:  Cancer Res       Date:  2013-05-30       Impact factor: 12.701

4.  Canolol inhibits gastric tumors initiation and progression through COX-2/PGE2 pathway in K19-C2mE transgenic mice.

Authors:  Donghui Cao; Jing Jiang; Tetsuya Tsukamoto; Ruming Liu; Lin Ma; Zhifang Jia; Fei Kong; Masanobu Oshima; Xueyuan Cao
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

Review 5.  Role of bile acids in colon carcinogenesis.

Authors:  Thi Thinh Nguyen; Trong Thuan Ung; Nam Ho Kim; Young Do Jung
Journal:  World J Clin Cases       Date:  2018-11-06       Impact factor: 1.337

6.  MicroRNA-204 Inhibits the Growth and Motility of Colorectal Cancer Cells by Downregulation of CXCL8.

Authors:  Feng Shuai; Bo Wang; Shuxiao Dong
Journal:  Oncol Res       Date:  2018-02-05       Impact factor: 5.574

Review 7.  The Chemokine CXCL8 in Carcinogenesis and Drug Response.

Authors:  Dominique Gales; Clarence Clark; Upender Manne; Temesgen Samuel
Journal:  ISRN Oncol       Date:  2013-10-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.